Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
Breast Cancer
DRUG: Gemcitabine,cisplatin|DRUG: Gemcitabine,carboplatin
PFS (Progression Free Survival), 6 weeks
Objective Response Rate (ORR), 6 weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 6 weeks|Overall Survival (OS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer.